U.S. markets open in 3 hours 48 minutes
  • S&P Futures

    4,260.25
    +5.50 (+0.13%)
     
  • Dow Futures

    34,402.00
    +21.00 (+0.06%)
     
  • Nasdaq Futures

    14,144.25
    +19.50 (+0.14%)
     
  • Russell 2000 Futures

    2,327.90
    +1.00 (+0.04%)
     
  • Crude Oil

    71.14
    +0.26 (+0.37%)
     
  • Gold

    1,866.30
    +0.40 (+0.02%)
     
  • Silver

    27.78
    -0.26 (-0.92%)
     
  • EUR/USD

    1.2129
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.45
    +0.80 (+5.11%)
     
  • GBP/USD

    1.4077
    -0.0031 (-0.22%)
     
  • USD/JPY

    110.1280
    +0.0670 (+0.06%)
     
  • BTC-USD

    40,086.37
    -11.24 (-0.03%)
     
  • CMC Crypto 200

    1,004.97
    +36.13 (+3.73%)
     
  • FTSE 100

    7,176.60
    +29.92 (+0.42%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

What Type Of Shareholders Make Up Prothena Corporation plc's (NASDAQ:PRTA) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls Prothena Corporation plc (NASDAQ:PRTA), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

Prothena isn't enormous, but it's not particularly small either. It has a market capitalization of US$1.2b, which means it would generally expect to see some institutions on the share registry. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Prothena.

View our latest analysis for Prothena

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Prothena?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Prothena does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Prothena, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Our data indicates that hedge funds own 25% of Prothena. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. EcoR1 Capital, LLC is currently the company's largest shareholder with 25% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 8.5% and 6.7%, of the shares outstanding, respectively.

We did some more digging and found that 6 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Prothena

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our data suggests that insiders own under 1% of Prothena Corporation plc in their own names. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own US$583k worth of shares. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

The general public holds a 13% stake in Prothena. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Prothena (at least 1 which makes us a bit uncomfortable) , and understanding them should be part of your investment process.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.